Literature DB >> 21670950

Reactivity of pulmonary circulation and right ventricle function to inhaled nitric oxide in systemic sclerosis patients.

Wojciech Plazak1, Krzysztof Gryga, Jan Sznajd, Joanna Wilisowska, Ewa Czarnobilska, Grzegorz Goncerz, Piotr Podolec, Jacek Musial.   

Abstract

Systemic sclerosis (SSc) is complicated by pulmonary hypertension and right ventricle (RV) failure in approximately 10% of the patients. Factors influencing the reactivity of pulmonary circulation to vasodilators are not established, while the examination of vasoreactivity is important in determining the treatment, because systemic administration of oral vasodilators can induce severe adverse events in nonresponders. The mechanism of RV failure in SSc is unclear and may result either from increased RV afterload or intrinsic myocardial disease. The aim of the study was to assess the reactivity of pulmonary circulation to inhaled nitric oxide (iNO) and to evaluate its influence on RV function in SSc patients with elevated right ventricle systolic pressure (RVSP). In 60 SSc patients aged 24-73 (58 females, two males; 33 patients with limited SSc and 27 with diffuse SSc), echocardiographic examination with tissue Doppler echocardiography (TDE) was performed. RV function was measured by systolic (S) and early diastolic (E) velocity of tricuspid annulus by TDE. In patients with RVSP >45 mmHg, the reactivity of pulmonary circulation was assessed by iNO test. High-resolution computerized tomography (HRCT) was performed to assess the extent of pulmonary fibrosis. Of 14 SSc subjects with elevated RVSP (13 females, one male; RVSP 47-62 mmHg), positive reaction to iNO was observed in five (RVSP decreased from 51.6 ± 3.7 to 32.24 ± 2.3 mmHg); nine patients were not reactive (RVSP 53.5 ± 5.7 mmHg before iNO vs. 49.6 ± 6.7 mmHg). RV systolic function was decreased in patients with elevated RVSP as compared to the patients with normal pulmonary pressure (S velocity 13.2 ± 1.3 vs. 14.4 ± 1.6 cm/s, respectively, p < 0.05). Significant increase of RV systolic function during iNO test was found in reactive patients only (S velocity before iNO 12.8 ± 1.2 cm/s, during iNO 14.5 ± 1.5 cm/s, p < 0.01). RVSP decrease strongly correlated with S velocity increase (r = 0.95, p < 0.0001). Response to iNO was found only in limited form of SSc; diffuse SSc patients showed no response. Pulmonary fibrosis on HRCT was more frequent in subjects nonreactive to iNO (67% of patients) than in the reactive group (40% of patients). The reactivity of pulmonary circulation to iNO in SSc patients with elevated RVSP was found predominantly in limited form of the disease. Pulmonary fibrosis typical for diffuse SSc was more frequent in nonreactive subjects. Elevated pulmonary pressure plays an important role in RV systolic dysfunction. Pulmonary pressure decrease during iNO test leads to the improvement of RV systolic function. Therapy for right-heart failure in reactive SSc patients should be directed, if possible, at the decrease in pulmonary resistance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670950      PMCID: PMC3249214          DOI: 10.1007/s10067-011-1792-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  14 in total

1.  Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension.

Authors:  Henrik ten Freyhaus; Daniel Dumitrescu; Henning Bovenschulte; Erland Erdmann; Stephan Rosenkranz
Journal:  Clin Res Cardiol       Date:  2009-02-13       Impact factor: 5.460

2.  Pulmonary arterial hypertension in systemic sclerosis: can we predict responders for successful therapy?

Authors:  Arthur A Sasahara
Journal:  J Rheumatol       Date:  2009-04       Impact factor: 4.666

3.  Right heart function in scleroderma: insights from myocardial Doppler tissue imaging.

Authors:  Shih-Hung Hsiao; Chiu-Yen Lee; Shu-Mei Chang; Shih-Kai Lin; Chun-Peng Liu
Journal:  J Am Soc Echocardiogr       Date:  2006-05       Impact factor: 5.251

4.  [Inducible nitric oxide synthase expression and nitric oxide production by monocytes in systemic sclerosis].

Authors:  C J Menkès; Y Allanore; D Borderie; P Hilliquin; A Hernvann; O Ekindjian; A Kahan
Journal:  Bull Acad Natl Med       Date:  2001       Impact factor: 0.144

5.  Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension.

Authors:  D J Williamson; C Hayward; P Rogers; L L Wallman; A D Sturgess; R Penny; P S Macdonald
Journal:  Circulation       Date:  1996-08-01       Impact factor: 29.690

6.  Heart structure and function in systemic sclerosis.

Authors:  Wojciech Plazak; Ewa Zabinska-Plazak; Anna Wojas-Pelc; Piotr Podolec; Maria Olszowska; Wieslawa Tracz; Jadwiga Bogdaszewska-Czabanowska
Journal:  Eur J Dermatol       Date:  2002 May-Jun       Impact factor: 3.328

7.  EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

Authors:  O Kowal-Bielecka; R Landewé; J Avouac; S Chwiesko; I Miniati; L Czirjak; P Clements; C Denton; D Farge; K Fligelstone; I Földvari; D E Furst; U Müller-Ladner; J Seibold; R M Silver; K Takehara; B Garay Toth; A Tyndall; G Valentini; F van den Hoogen; F Wigley; F Zulian; Marco Matucci-Cerinic
Journal:  Ann Rheum Dis       Date:  2009-01-15       Impact factor: 19.103

8.  Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization.

Authors:  Vivien M Hsu; Abel E Moreyra; Alan C Wilson; Meir Shinnar; Daniel M Shindler; Julianne E Wilson; Ami Desai; James R Seibold
Journal:  J Rheumatol       Date:  2008-01-15       Impact factor: 4.666

9.  Usefulness of right ventricular isovolumic relaxation time in predicting systolic pulmonary artery pressure.

Authors:  Nicolas Bréchot; Laetitia Gambotti; Stéphane Lafitte; Raymond Roudaut
Journal:  Eur J Echocardiogr       Date:  2008-03-14

10.  Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma.

Authors:  Gabor Kovacs; Robert Maier; Elisabeth Aberer; Marianne Brodmann; Stefan Scheidl; Natascha Tröster; Christian Hesse; Wolfgang Salmhofer; Winfried Graninger; Ekkehard Gruenig; Lewis J Rubin; Horst Olschewski
Journal:  Am J Respir Crit Care Med       Date:  2009-08-13       Impact factor: 21.405

View more
  2 in total

1.  Vaso reactivity test using inhaled nitric oxide for pulmonary arterial hypertension accompanied by severe interstitial lung disease attributed to systemic sclerosis: A case report.

Authors:  Tomohiro Yamaguchi; Yasuhiro Izumiya; Ou Hayashi; Hiroya Hayashi; Mana Ogawa; Atsushi Shibata; Takanori Yamazaki; Minoru Yoshiyama
Journal:  J Cardiol Cases       Date:  2021-08-31

Review 2.  Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases.

Authors:  Ayodeji Adegunsoye; Matthew Levy; Olusegun Oyenuga
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.